[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521105":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":23,"interventions":36,"overallOfficials":54,"centralContacts":59,"locations":65,"responsibleParty":79,"collaborators":13,"id":82,"slug":13,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":13,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":13,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":102,"whyStopped":13,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Damascus Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Eradication rate of Helicobacter pylori infection","Eradication rate of Helicobacter infected patients","8 week from begning of treatment",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"DOUBLE",[21,22],"INVESTIGATOR","OUTCOMES_ASSESSOR",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"sequential","EXPERIMENTAL","Measure eradication rate of Helicobacter pylori infection with Levofloxacien sequential based regimen",[29],"Drug: sequential",{"label":31,"type":32,"description":33,"interventionNames":34},"concomitant","ACTIVE_COMPARATOR","Measure eradication rate of Helicobacter pylori infection with Livofloxacine concomitant based regimen",[35],"Drug: Levofloxacin 500Mg Oral Tablet",[37,46],{"type":38,"name":25,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week",[25],[42,43,44,45],"Esomeprazole","levofloxacine","metronidazole","amoxicillin",{"type":38,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Levofloxacin 500Mg Oral Tablet","Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid",[31],[51,52,53],"Amoxicilline","Esomeprazol","Tinadizole",[55],{"name":56,"affiliation":57,"role":58},"Marouf M Alhalabi, MD","general assambly of damascus hospital","PRINCIPAL_INVESTIGATOR",[60],{"name":61,"role":62,"phone":63,"phoneExt":13,"email":64},"Marouf MH Alhalabi, MD","CONTACT","+963952781278","e.marouf@hotmail.com",[66],{"facility":67,"status":13,"city":68,"state":13,"zip":13,"country":69,"countryCode":13,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"General Assembly of Damascus Hospital","Damascus","Syria",{"type":71,"coordinates":72},"Point",[73,74],36.29128,33.5102,{"lat":74,"lon":73},[77],{"name":78,"role":62,"phone":63,"phoneExt":13,"email":64},"Marouf MI Alhalabi, MD",{"type":58,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Marouf Alhalabi","head of digestive diseases department","100521105",false,"NCT06065267","Levofloxacin Concomitant Versus Levofloxacin Sequential","Efficacy of Two-week Therapy With Levofloxacin-based Concomitant Regimen Versus Levofloxacin-based Sequential Regimen for Helicobacter Pylori Infection in Syrian Population: a Prospective Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods:\n* Positive rapid urease test (CLOtest).\n* Histologic evidence of H. pylori by modified Giemsa staining.\n* Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy.\n\nExclusion Criteria:\n\n* Children and teenagers aged less than 18 years.\n* Previous eradication treatment for H. pylori.\n* Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.\n* History of gastrectomy.\n* Gastric malignancy, including adenocarcinoma and lymphoma,\n* Previous allergic reaction to antibiotics (Amoxicillin, Tinadizole,\n* Doxycycline,Bismuth subsalicylate,) and prompt pump inhibitors (Es- omeprazole).\n* Contraindication to treatment drugs.\n* Pregnant or lactating women.\n* Severe concurrent disease.\n* Liver cirrhosis.","ALL","18 Years","80 Years",{"count":92,"type":93},150,"ESTIMATED","INTERVENTIONAL",[96],"PHASE4","The goal of this trial is to determine the efficacy of levofloxacin based sequential treatment regimen or concomitant levofloxacin based regimens as empirical first-line therapy in the Syrian population",[99],"Helicobacter Pylori Infection",[101,43,31,25],"Helicobacter Pylori","NOT_YET_RECRUITING","2023-09-27",{"date":105,"type":106},"2023-10-03","ACTUAL",{"date":108,"type":93},"2024-01-02",{"date":110,"type":93},"2027-06-30",{"name":5,"class":6},1]